Patients without hepatocellular carcinoma progression after transarterial chemoembolization benefit from liver transplantation

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 5

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

361

HTML

1100

Figures (1-6)

140

Tables (1-4)

Sum=1698

Feb 7, 2007 (publication date) through May 7, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Research

World J Gastroenterol. Feb 7, 2007; 13(5): 761-767
Published online Feb 7, 2007. doi: 10.3748/wjg.v13.i5.761

Table 4 Treatment modalities of patients with HCC

Treatment	n	No cirrhosis	Cirrhosis
No treatment	10	3	7
TACE, not listed for OLT	32	6	41
TACE, died waiting for OLT	15
TACE and liver transplantation	20	0	20
Liver transplantation	7	1	6
Total	84	10	74

Citation: Obed A, Beham A, Püllmann K, Becker H, Schlitt HJ, Lorf T. Patients without hepatocellular carcinoma progression after transarterial chemoembolization benefit from liver transplantation. World J Gastroenterol 2007; 13(5): 761-767
URL: https://www.wjgnet.com/1007-9327/full/v13/i5/761.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i5.761